{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:03:26Z","timestamp":1792494206999,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390900677"],"award-info":[{"award-number":["390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ependymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical resection alone. A substantial proportion of these tumors recurs or displays infiltrative growth patterns. Further established therapeutic options include radiation therapy. Systemic treatment options include platinum-based therapeutic regimes or a combination of lapatinib and temozolomide. Peptide-based immunotherapy represents a promising therapeutic strategy relying on the induction of tumor-specific T cells targeting human leukocyte antigens (HLA)-presented peptides. Our work aimed to analyze the landscape of naturally presented HLA class I and II ligands of primary ependymomas (EPN) to delineate EPN-associated antigens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We investigated 22 EPN tissue samples using a comparative mass spectrometry-based immunopeptidomic approach. Additionally, EPN-specific antigens were functionally characterized in T-cell-based immunogenicity assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We discovered a subset of EPN-exclusive peptides including HLA-A*02 and HLA-A*25\/HLA-A*26\u2013restricted HLA ligands and identified a small panel of cancer\/testis antigens (CTAs)-derived HLA ligands. Furthermore, we outlined immunopeptidomic alterations in different ependymoma subgroups and progressive ependymoma. Subsequently, we performed functional characterization of the previously identified HLA-A*02:01 restricted peptide FLDS to demonstrate immunogenicity in vitro.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The immunopeptidome landscape of EPNs provides actionable targets that could further be explored as a T cell-based immunotherapeutic strategy in this tumor entity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae226","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:28:01Z","timestamp":1737026881000},"source":"Crossref","is-referenced-by-count":2,"title":["The immunopeptidomic landscape of ependymomas provides actionable antigens for T-cell-based immunotherapy"],"prefix":"10.1093","volume":"7","author":[{"given":"Lena","family":"M\u00fchlenbruch","sequence":"first","affiliation":[{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rieger","sequence":"additional","affiliation":[{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maia","family":"Santos Leite","sequence":"additional","affiliation":[{"name":"Institute for Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"M\u00e4urer","sequence":"additional","affiliation":[{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Dubbelaar","sequence":"additional","affiliation":[{"name":"Quantitative Biology Center (QBiC), Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Institute for Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Bichmann","sequence":"additional","affiliation":[{"name":"Applied Bioinformatics, Department of Computer Science, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Institute for Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-4598","authenticated-orcid":false,"given":"Oliver","family":"Kohlbacher","sequence":"additional","affiliation":[{"name":"Institute for Bioinformatics and Medical Informatics, University of Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Institute for Translational Bioinformatics, University Hospital Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence Machine Learning in the Sciences (EXC2064), University of Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Applied Bioinformatics, Department of Computer Science, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Institute for Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Gouttefangeas","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Institute for Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neurosurgery, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane S","family":"Walz","sequence":"additional","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Personalized Medicine, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University Tuebingen , 72076 Tuebingen, Baden-Wuerttemberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"4","key":"2025052714112759500_CIT0001","doi-asserted-by":"crossref","first-page":"e13068","DOI":"10.1111\/bpa.13068","article-title":"Updates in the classification of ependymal neoplasms: the 2021 WHO classification and beyond","volume":"32","author":"Kresbach","year":"2022","journal-title":"Brain Pathol."},{"issue":"8","key":"2025052714112759500_CIT0002","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/noq009","article-title":"Adult ependymal tumors: prognosis and the M. D. Anderson cancer center experience","volume":"12","author":"Armstrong","year":"2010","journal-title":"Neuro Oncol"},{"key":"2025052714112759500_CIT0003","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"4","key":"2025052714112759500_CIT0004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3171\/2008.9.JNS08117","article-title":"Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study","volume":"110","author":"McGuire","year":"2009","journal-title":"J Neurosurg."},{"issue":"3","key":"2025052714112759500_CIT0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/neuonc\/nou162","article-title":"Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients","volume":"17","author":"Vera-Bolanos","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025052714112759500_CIT0006","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/1541-7786.MCR-08-0584","article-title":"Pediatric ependymoma: biological perspectives","volume":"7","author":"Kilday","year":"2009","journal-title":"Mol Cancer Res."},{"issue":"6","key":"2025052714112759500_CIT0007","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","article-title":"MYCN amplification drives an aggressive form of spinal ependymoma","volume":"138","author":"Ghasemi","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2025052714112759500_CIT0008","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"2025052714112759500_CIT0009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00401-018-1877-0","article-title":"Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas","volume":"136","author":"Pajtler","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2025052714112759500_CIT0010","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bpa.12866","article-title":"cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors","volume":"30","author":"Ellison","year":"2020","journal-title":"Brain Pathol."},{"issue":"8","key":"2025052714112759500_CIT0011","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"2025052714112759500_CIT0012","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11060-018-2815-7","article-title":"Patterns of relapse for children with localized intracranial ependymoma","volume":"138","author":"De","year":"2018","journal-title":"J Neurooncol."},{"issue":"4","key":"2025052714112759500_CIT0013","first-page":"475","article-title":"Chemotherapy for adult patients with spinal cord gliomas","volume":"8","author":"Gramatzki","year":"2021","journal-title":"Neurooncol Pract.."},{"key":"2025052714112759500_CIT0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-016-2323-0","article-title":"Chemotherapy for intracranial ependymoma in adults","volume":"16","author":"Gramatzki","year":"2016","journal-title":"BMC Cancer"},{"issue":"7686","key":"2025052714112759500_CIT0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature25169","article-title":"Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling","volume":"553","author":"Mack","year":"2018","journal-title":"Nature."},{"issue":"1","key":"2025052714112759500_CIT0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12967-021-02834-1","article-title":"Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis","volume":"19","author":"Wang","year":"2021","journal-title":"J Transl Med."},{"issue":"2","key":"2025052714112759500_CIT0017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00262-018-2278-x","article-title":"Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma","volume":"68","author":"Nam","year":"2019","journal-title":"Cancer Immunol Immunother."},{"issue":"4","key":"2025052714112759500_CIT0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10014-019-00350-1","article-title":"Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade","volume":"36","author":"Nambirajan","year":"2019","journal-title":"Brain Tumor Pathol."},{"issue":"5","key":"2025052714112759500_CIT0019","doi-asserted-by":"crossref","first-page":"e26960","DOI":"10.1002\/pbc.26960","article-title":"Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy","volume":"65","author":"Witt","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2025052714112759500_CIT0020","doi-asserted-by":"crossref","first-page":"e236242","DOI":"10.1136\/bcr-2020-236242","article-title":"Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response","volume":"13","author":"Tapia Rico","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2025052714112759500_CIT0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/reports4020012","article-title":"Targeted therapy with sirolimus and nivolumab in a child with refractory multifocal anaplastic ependymoma","volume":"4","author":"Perruccio","year":"2021","journal-title":"Reports"},{"issue":"1","key":"2025052714112759500_CIT0022","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience","volume":"149","author":"Cacciotti","year":"2020","journal-title":"J Neurooncol."},{"issue":"5","key":"2025052714112759500_CIT0023","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med."},{"issue":"46","key":"2025052714112759500_CIT0024","doi-asserted-by":"crossref","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2025052714112759500_CIT0025","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmeth1113","article-title":"Semi-supervised learning for peptide identification from shotgun proteomics datasets","volume":"4","author":"K\u00e4ll","year":"2007","journal-title":"Nat Methods."},{"issue":"3-4","key":"2025052714112759500_CIT0026","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics."},{"issue":"9","key":"2025052714112759500_CIT0027","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol."},{"key":"2025052714112759500_CIT0028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics."},{"issue":"1","key":"2025052714112759500_CIT0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1471-2105-15-293","article-title":"jvenn: an interactive Venn diagram viewer","volume":"15","author":"Bardou","year":"2014","journal-title":"BMC Bioinf."},{"issue":"6","key":"2025052714112759500_CIT0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2025052714112759500_CIT0031","doi-asserted-by":"crossref","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA ligand atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J ImmunoTher Cancer."},{"issue":"D1","key":"2025052714112759500_CIT0032","doi-asserted-by":"crossref","first-page":"D394","DOI":"10.1093\/nar\/gkaa1106","article-title":"PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API","volume":"49","author":"Mi","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"2025052714112759500_CIT0033","doi-asserted-by":"crossref","first-page":"D442","DOI":"10.1093\/nar\/gky1106","article-title":"The PRIDE database and related tools and resources in 2019: improving support for quantification data","volume":"47","author":"Perez-Riverol","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2025052714112759500_CIT0034","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/ncomms2610","article-title":"Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons","volume":"4","author":"Sturm","year":"2013","journal-title":"Nat Commun."},{"key":"2025052714112759500_CIT0035","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3389\/fimmu.2019.02526","article-title":"A Non-interventional clinical trial assessing immune responses after radiofrequency ablation of liver metastases from colorectal cancer","volume":"10","author":"L\u00f6ffler","year":"2019","journal-title":"Front Immunol."},{"issue":"21","key":"2025052714112759500_CIT0036","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/cells11213451","article-title":"Simultaneous identification of functional antigen-specific CD8(+) and CD4(+) cells after in vitro expansion using elongated peptides","volume":"11","author":"Schuhmacher","year":"2022","journal-title":"Cells"},{"issue":"12","key":"2025052714112759500_CIT0037","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-21-4424","article-title":"Phase I\/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma","volume":"28","author":"L\u00f6ffler","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2025052714112759500_CIT0038","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nprot.2012.037","article-title":"Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers","volume":"7","author":"Andersen","year":"2012","journal-title":"Nat Protoc"},{"issue":"1","key":"2025052714112759500_CIT0039","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cyto.a.22575","article-title":"Cryopreservation of MHC multimers: recommendations for quality assurance in detection of antigen specific T cells","volume":"87","author":"Hadrup","year":"2015","journal-title":"Cytometry A."},{"key":"2025052714112759500_CIT0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinf."},{"issue":"D1","key":"2025052714112759500_CIT0041","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"2025052714112759500_CIT0042","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"2025052714112759500_CIT0043","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","year":"2013","journal-title":"Nat Genet."},{"issue":"6","key":"2025052714112759500_CIT0044","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00401-018-1836-9","article-title":"The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy","volume":"135","author":"Neidert","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"Database issue","key":"2025052714112759500_CIT0045","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"2025052714112759500_CIT0046","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4049\/jimmunol.1700242","article-title":"Peptide-MHC class I tetramers can fail to detect relevant functional T cell clonotypes and underestimate antigen-reactive T cell populations","volume":"200","author":"Rius","year":"2018","journal-title":"J Immunol."},{"issue":"2","key":"2025052714112759500_CIT0047","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-016-3743-x","article-title":"Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer","volume":"156","author":"Matsumoto","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"2 Pt 1","key":"2025052714112759500_CIT0048","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2025052714112759500_CIT0049","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2018.36.15_suppl.2000","article-title":"GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma","volume":"36","author":"Wick","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025052714112759500_CIT0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.06.027","article-title":"Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient","volume":"65","author":"L\u00f6ffler","year":"2016","journal-title":"J Hepatol."},{"issue":"7662","key":"2025052714112759500_CIT0051","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"issue":"7662","key":"2025052714112759500_CIT0052","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature."},{"key":"2025052714112759500_CIT0053","doi-asserted-by":"crossref","first-page":"883989","DOI":"10.3389\/fimmu.2022.883989","article-title":"The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies","volume":"13","author":"Becker","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"2025052714112759500_CIT0054","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cancers12030535","article-title":"Mass spectrometry-based identification of MHC-associated peptides","volume":"12","author":"Kote","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"2025052714112759500_CIT0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia."},{"issue":"10","key":"2025052714112759500_CIT0056","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood."},{"issue":"16","key":"2025052714112759500_CIT0057","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/0008-5472.CAN-17-1745","article-title":"Mapping the HLA ligandome of colorectal cancer reveals an imprint of malignant cell transformation","volume":"78","author":"L\u00f6ffler","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"2025052714112759500_CIT0058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11060-012-1028-8","article-title":"Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy","volume":"111","author":"Neidert","year":"2013","journal-title":"J Neurooncol."},{"issue":"Pt 4","key":"2025052714112759500_CIT0059","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/brain\/aws042","article-title":"Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy","volume":"135","author":"Dutoit","year":"2012","journal-title":"Brain."},{"issue":"10","key":"2025052714112759500_CIT0060","doi-asserted-by":"crossref","first-page":"e003404","DOI":"10.1136\/jitc-2021-003404","article-title":"Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors","volume":"9","author":"Marcu","year":"2021","journal-title":"J ImmunoTher Cancer."},{"issue":"6","key":"2025052714112759500_CIT0061","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","article-title":"Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells","volume":"4","author":"Nelde","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2025052714112759500_CIT0062","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol."},{"issue":"8","key":"2025052714112759500_CIT0063","doi-asserted-by":"crossref","first-page":"e002899","DOI":"10.1136\/jitc-2021-002899","article-title":"Deregulation of HLA-I in cancer and its central importance for immunotherapy","volume":"9","author":"Hazini","year":"2021","journal-title":"J ImmunoTher Cancer."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae226\/61457968\/vdae226.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae226\/61457968\/vdae226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae226\/61457968\/vdae226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:11:41Z","timestamp":1748369501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae226\/7958303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae226","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdae226"}}